[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Novo Nordisk A\u002FS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":539},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,76,0,25,[9,42,67,88,108,130,149,170,191,213,235,257,277,296,316,337,356,377,400,420,438,459,478,499,518],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100608919","phase-3-cleopattra-a-research-study-to-look-at-the-effects-of-treatment-with-a-medicine-called-coramitug-nnc6019-0001-in-people-with-heart-failure-due-to-transthyretin-amyloid-attr-amyloidosis-100608919",false,"NCT07207811","CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis","CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)","CLEOPATTRA","Inclusion Criteria:\n\n1. Male or female.\n2. Age 18 years or above at the time of signing the informed consent.\n3. Have an established diagnosis of ATTR-CM (wild-type ATTR \\[ATTRwt\\] or variant ATTR \\[ATTRv\\]), with cardiac amyloid infiltration, increased left ventricular (LV) wall thickness, and HF.\n\n   Note: Target ATTRv recruitment is approximately 15 percent of the study population.\n\n   a. Cardiac amyloid infiltration demonstrated by: i. Cardiac biopsy positive for TTR amyloid, OR ii. Grade 2 or 3 cardiac uptake at pyrophosphate (PYP)\u002Fdiphosphono-1,2-propanodicarboxylic acid (DPD)\u002F hydroxymethylene diphosphonate (HMDP) nuclear medicine imaging with single-photon emission computed tomography (SPECT) or SPECT\u002FCT (preferably) combined with an extracardiac biopsy positive for TTR amyloid, OR iii. Grade 2 or 3 cardiac uptake at PYP\u002FDPD\u002FHMDP nuclear medicine imaging with SPECT or SPECT\u002FCT (preferably) combined with normal serum free light chain ratio, and negative serum and urine protein electrophoresis with immunofixation (SPIE \\& UPIE)\u002For mass spectrometry based methods including mass fixation).\n\n   Notes:\n   * Non-invasive diagnostic pathway will be confirmed by a centralised expert review.\n   * Bone tracer nuclear medicine imaging with SPECT or SPECT\u002FCT (preferably) will be conducted using 99m-technetium (Tc)-labelled pyrophosphate (99mTc-PYP), 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD), or 99mTc-labeled hydroxymethylene diphosphonate (99mTc-HMDP).\n   * The eGFR adjusted acceptable serum free light chain ratio.\n   * Patients with Grade 2 or 3 cardiac uptake at PYP\u002FDPD\u002FHDMP nuclear imaging with SPECT or SPECT\u002FCT (preferably) and evidence of monoclonal gammopathy of undetermined significance (MGUS; based on serum and urine protein electrophoresis and serum free light chains) will require endomyocardial biopsy with typing using mass spectrometry or immunohistochemistry to confirm presence of TTR protein in tissue.\n   * Timing of serum free light chain ratio, SPIE, UPIE and mass spectrometry-based methods including mass fixation should be within 12 months of SPECT or SPECT\u002FCT nuclear imaging.\n\n     b. Increased LV wall thickness, as assessed by centralised review of echocardiography, showing interventricular septal wall thickness greater than or equal to 12 millimeter (mm).\n\n     c. Chronic HF (New York Heart Association \\[NYHA\\] Class I-IV): i. At least 1 documented hospitalisation for HF, OR ii. History of HF manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath, signs of pulmonary congestion on x-ray or auscultation, or peripheral oedema that required or requires ongoing treatment with a diuretic).\n4. Expected to be on stable cardiovascular medical therapy (defined as no greater than 50 percent dose adjustment and no categorical changes of medications), with the exception of diuretics, 4 weeks prior to the randomisation visit.\n5. Completed more than 50 meters on the 6MWT at screening.\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to study intervention(s) or related products.\n2. Current or previous participation (dosing with active treatment) in a study for an investigational ATTR depleting drug or ATTR gene editing therapy.\n3. Total bilirubin greater than 3 times the upper limit of normal (ULN) at screening.\n4. Current diagnosis or history of amyloid light chain, other non-ATTR amyloidosis, known leptomeningeal amyloidosis, or multiple myeloma.\n5. HF not primarily caused by ATTR-CM (e.g., due to hypertension, valvular heart disease, or ischemic heart disease in the opinion of the investigator).\n6. Currently hospitalised or hospitalised within 14 days prior to screening.\n7. Currently treated with positive inotropic medication.\n8. Uncorrected, severe, haemodynamically significant, left-sided heart valve disease.\n9. Acute coronary syndrome, unstable angina, stroke, transient ischemic attack, coronary revascularisation, cardiac device implantation, cardiac valve repair, or major surgery within 60 days of screening.\n10. Prior solid organ transplant or planned solid organ transplant during the study.\n11. Left ventricular ejection fraction (LVEF) less than 30 percent as assessed by centralised review of echocardiography.\n12. Presence or history of malignant neoplasm (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, carcinoma in situ\u002Fhigh-grade prostatic intraepithelial neoplasia \\[PIN\\], low-risk prostate cancer, or on stable therapy for prostate cancer) within 3 years before screening.\n13. End-stage renal disease (estimated glomerular filtration rate \\[eGFR\\] less than 15 mL\u002Fmin\u002F1.73 m\\^2 at screening, or chronic\u002Fintermittent haemodialysis or peritoneal dialysis).","ALL","18 Years",{"count":21,"type":22},1280,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.",[28],"Transthyretin Amyloid Cardiomyopathy (ATTR CM)","RECRUITING","2026-08-18",{"date":32,"type":33},"2026-08-19","ACTUAL",{"date":35,"type":33},"2025-10-02",{"date":37,"type":22},"2029-06-29",{"name":39,"class":40},"Novo Nordisk A\u002FS","INDUSTRY",295,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100646253","phase-1-a-study-to-see-how-safe-a-new-medicine-nnc6022-0004-is-in-healthy-people-and-people-living-with-obesity-100646253","NCT07693868","A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity","An NNC6022-0004 Single and Multiple Ascending Dose Study Investigating Safety, Tolerability, Pharmacokinetics, Food Effect and Target Engagement in Healthy Adults Including a Single Cohort in Adults Living With Obesity","Inclusion Criteria:\n\n* Male, or female of non-childbearing potential.\n* For Parts A, B, C and D: Age 18-55 years (both inclusive) at the time of signing the informed consent.\n\nFor optional Part E only: Age 18-65 years (both inclusive) at the time of signing the informed consent.\n\n-For Parts A, B, C and D: Body mass index (BMI) between 18.5 to 29.9 kilogram per meter square (kg\u002Fm\\^2) (both inclusive) at screening.\n\nFor optional Part E only: BMI between greater than or equal to (≥) 30.0 to less than or equal to (≤) 45.0 kg\u002Fm\\^2 at screening, or if BMI is between 27.0 and \\\u003C30.0 kg\u002Fm\\^2, waist to height ratio should be greater than (\\>)0.5.\n\n* Body weight: ≥50.0 kilogram (kg) at screening.\n* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n* For optional Part E only: hsCRP ≥2.00 and ≤8.00 milligrams per liter (mg\u002FL) during screening period in 2 separate samples taken ≥4 days apart.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or similar products.\n* Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Any of the below laboratory safety parameters at screening outside normal range, see designated reference range documents for specific values.\n* Alanine Aminotransferase (ALT) \\> Upper limit of normal (ULN).\n* Alkaline Phosphatase (ALP) \\> ULN.\n* Aspartate aminotransferase (AST) \\> ULN.\n* Total Bilirubin (TBL) \\> ULN.\n* Creatinine \\> ULN.\n* International normalized ratio (INR) \\> ULN.\n* Fibrinogen outside normal range of 1.6 - 4.2 grams per liter (g\u002FL).\n* hsCRP \\> 5.00 mg\u002FL (males) and \\> 8.00 mg\u002FL (females)\\*.\n\n  * applicable for Parts A, B, C and D and for optional Part E: hsCRP \\>8.00 mg\u002FL.\n* Use of prescription medicinal products or vaccines within 14 days before screening and\u002For non prescription medicinal products within 7 days before dosing. Exceptions are: Topical medications not reaching systemic circulation; less than once per week of over-the-counter paracetamol, ibuprofen and\u002For acetylsalicylic acid at their labelled doses for mild pain; vitamins at their labelled doses.",true,"65 Years",{"count":52,"type":22},128,[54],"PHASE1","This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.",[57,58],"Obesity","Elevated High-sensitivity C-reactive Protein (hsCRP)","2026-08-17",{"date":32,"type":33},{"date":62,"type":33},"2026-07-06",{"date":64,"type":22},"2027-08-01",{"name":39,"class":40},1,{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100636539","phase-3-a-research-study-to-look-at-how-well-nnc0487-0111-works-compared-to-placebo-in-people-with-heart-failure-and-obesity-100636539","NCT07567001","A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity","Efficacy and Safety of NNC0487-0111 Compared to Placebo on Morbidity and Mortality in People With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity","HF-POLARIS","Inclusion Criteria:\n\n* Body Mass Index (BMI) greater than or equal to (\\>=) 30 kilograms per square metre (kg\u002Fm\\^2) at screening.\n* Diagnosis of HF with New York Heart Association (NYHA) class II-IV and in stable condition at screening, at the discretion of the investigator.\n\nFor participants with Type 2 Diabetes (T2D) at screening:\n\n\\- Diagnosed with T2D \\>= 30 days before screening.\n\nExclusion Criteria:\n\n* MI, stroke, unstable angina pectoris or worsening HF leading to either hospitalization or intravenous loop diuretics within 30 days prior to the day of screening and until randomization.\n* HF due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, Chagas cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, or uncorrected primary valve disease of moderate or severe degree.\n* Severe pulmonary disease including primary pulmonary hypertension, chronic pulmonary embolism, or severe chronic obstructive pulmonary disease (COPD) defined as:\n* requiring home oxygen; or - ongoing oral corticosteroid therapy; or - hospital for COPD Exacerbation within 12 months prior to screening.\n* Any other condition judged by the investigator to be the cause of HF symptoms (e.g., anaemia, hypothyroidism).\n\nGlycaemia-related:\n\n* History of type 1 diabetes.\n* Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or who, at the time of screening, are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Glycated haemoglobin (HbA1c) greater than (\\>) 10 percent (%) (86 \\[millimoles per mole\\] mmol\u002Fmol) as measured by local or central laboratory at screening.",{"count":76,"type":22},5610,[25],"This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.",[57,80],"Heart Failure",{"date":30,"type":33},{"date":83,"type":33},"2026-05-11",{"date":85,"type":22},"2029-08-15",{"name":39,"class":40},838,{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":12,"sex":18,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":66},"100609749","phase-1-a-research-study-on-the-effects-of-nnc0537-1482-in-participants-with-heart-failure-100609749","NCT07218627","A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure","A Randomised, Placebo-controlled, Double-blinded Phase 1b Study Investigating Safety, Tolerability, Pharmacokinetics and Effects on Biomarkers From Multiple Ascending Doses of NNC0537-1482 in Participants With Heart Failure","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Male or females of non-childbearing potential.\n* Age 40-75 years (both inclusive) at the time of signing the informed consent.\n* Body Mass Index (BMI) range 18.5 - less than (\\\u003C) 40 kilograms per square meter (kg\u002Fm\\^2).\n* Symptomatic heart failure (New York Heart Association class II-III).\n* Stable standard of care medical therapy for heart failure with mildly reduced ejection fraction\u002Fheart failure with preserved ejection fraction (HFmrEF\u002FHFpEF) defined by:\n* No addition or removal of sodium-glucose cotransporter 2 inhibitors (SGLT2i), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (BBs,) calcium-channel blockers or aldosterone antagonists, and no substantial change in dosage (greater than or equal to (≥)100% increase\u002Fdecrease) at least 4 weeks before screening.\n* On a diuretic therapy at least 2 weeks before screening without substantial change in dosing (≥50% increase\u002Fdecrease), and on a stable diuretic therapy at least 1 week before screening.\n* On the stable doses (not in titration period) of standard medical therapy for other comorbidities\n* No hospitalizations due to heart failure (HF) between screening (V1) and randomisation (V2) confirmed at randomisation.\n* Left ventricle ejection fraction (LVEF) greater than (\\>) 40 percentage (%) documented by echocardiography at screening, or within 12 months prior to screening with no change in clinical status suggesting potential for deterioration in systolic function.\n\nAND at least one of the following:\n\n* N-terminal pro type-B natriuretic peptide (NT-proBNP) ≥125 picogram per milliliter (pg\u002FmL) (for participants with sinus rhythm) or NT-proBNP ≥375 pg\u002FmL (for participants with persistent\u002Fpermanent atrial fibrillation) at screening, and ≥1 of the following (documented by echocardiography within 12 months prior to or at screening):\n* Septal é \\\u003C7 or lateral \\\u003C10 or average E\u002Fé ≥10\n* Pulmonary artery (PA) systolic pressure \\>35 millimeters of mercury (mmHg)\n* Left atrium (LA) enlargement, (width ≥3.8 centimeter (cm) or length ≥5.0 cm or area ≥20.0 square centimeter (cm\\^2) or volume ≥55 milliliter (mL) or left atrial volume index (LAVI) ≥29 milliliter per square meter (mL\u002Fm\\^2)\n* Left ventricular hypertrophy (LVH) with septal thickness or posterior wall thickness ≥1.2 cm.\n* Hospitalization with a primary diagnosis of decompensated HF requiring intravenous loop diuretic treatment within previous 12 months, and ≥2 of the following (documented by echocardiography within 12 months prior to or at screening):\n* Septal é \\\u003C7 or lateral \\\u003C10 or average E\u002Fé ≥10\n* PA systolic pressure \\>35 mmHg\n* LA enlargement, (width ≥3.8 cm or length ≥5.0 cm or area ≥20.0 cm\\^2 or volume ≥55 mL or LAVI ≥29 mL\u002Fm\\^2)\n* LVH with septal thickness or posterior wall thickness ≥1.2 cm\n* Ongoing use of diuretic therapy for ≥30 days before screening.\n* Mean pulmonary capillary wedge pressure (PWP) ≥15 mmHg or left ventricular end-diastolic pressure (LVEDP) ≥15 mmHg documented during catheterization at rest or PA diastolic pressure measured by implantable monitor ≥15 mmHg or PWP or LVEDP ≥25 mmHg documented during catheterization at exercise.\n\nExclusion Criteria:\n\n* Any prior echo measurement of LVEF less than or equal to (≤) 40%, under stable conditions, within the past 36 months.\n* Previous participation in this study (defined as being randomised).\n* Ongoing treatment with a neprilysin inhibitor (including angiotensin receptor\u002Fneprilysin inhibitor treatment), phosphodiesterase-5 (PDE5) inhibitors or soluble guanylate cyclase (sGC) stimulators.\n* Acute coronary syndrome (ACS) (including myocardial infarction (MI)), stroke, transient ischemic attack (TIA), carotid surgery or angioplasty, cardiac surgery, other major cardiovascular surgery, or urgent percutaneous coronary intervention within the 3 months prior to screening.\n* Current acute decompensated HF requiring augmented therapy.\n* Hospitalisation within the last 90 days prior to screening with HF as the primary cause.\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Probable alternative diagnoses that in the opinion of the investigator could account for the participant's HF symptoms (i.e., dyspnoea, fatigue) such as significant pulmonary disease (including primary pulmonary hypertension, severe chronic obstructive pulmonary disease), anaemia, hypothyroidism or obesity.\n* Systolic blood pressure outside the range of 110-160 mmHg at screening or randomisation.\n* Heart rate outside the range of 40-110 beats per minute (bpm) at screening or randomisation.\n* Orthostatic hypotension (defined as a decrease in systolic blood pressure ≥20 mmHg or a decrease in diastolic blood pressure ≥10 mmHg from a supine position to standing after 3 minutes, at screening or randomisation).\n* Atrioventricular-block II or III, QRS \\>120 milliseconds (ms), or QTcF interval \\>450 ms for men and \\>470 ms for women, or any other clinically significant abnormal electrocardiogram (ECG) results as judged by the investigator at screening or randomisation.\n* Participant has pacemaker, or implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy (CRT) or left ventricular assist device (LVAD).\n* Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or flutter with a resting ventricular rate \\>110 bpm at screening or at randomisation.\n* Significant changes of prescription medicinal products (dose or frequency) or non-prescription drugs between screening and randomisation visits, per investigator's assessment.\n* Blood donation, plasma donation or blood draw any of the circumstances below:\n* 400 mL within the past 90 days prior to the day of screening\n* 50 mL within the past 30 days prior to the day of screening.\n* Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention within the 3 months after screening.\n* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≥2 times upper limit of normal (ULN).\n* Estimated glomerular filtration (eGFR) \\\u003C20 milliliter per minute per 1.73 square meter according to 2021 CKD-EPI equation.\n* History or presence of any other disease (i.e., including malignancies) with a life expectancy of \\\u003C1 year at screening.\n* Receiving insulin for the treatment of diabetes type 1 or diabetes type 2.\n* Glycated haemoglobin (HbA1c) of \\> 8.0% as measured at screening.","40 Years","75 Years",{"count":98,"type":22},36,[54],"The study is testing a new drug (NNC0537-1482) to potentially treat people with heart failure. The purpose of the study is to see if NNC0537-1482 is safe and how it works in the body. Participants will either get NNC0537-1482 or placebo (a \"dummy drug\" without any active ingredients) and which treatment they get is decided by chance. This study will last up to 64 days with an additional screening period up to 28 days.",[80],{"date":30,"type":33},{"date":104,"type":33},"2025-10-23",{"date":106,"type":22},"2027-01-15",{"name":39,"class":40},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":66},"100652173","phase-1-study-to-assess-tolerability-of-injecting-larger-volumes-2-5-ml-subcutaneously-at-different-rates-participant-experience-and-acceptance-100652173","NCT07769489","Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance","An Exploratory Study to Investigate Pain Related to Injection of Large Volumes (up to 5mL) Subcutaneously","RISE","Inclusion criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Healthy male or female participants as judged by the investigator.\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n* Body Mass Index (BMI) greater than or equal to (\\>=) 18.5 and less than or equal to (\\\u003C=) 30.0 kilograms per square metre (kg\u002Fm\\^2) (both included).\n* White (Light skin that allows for adequate medical evaluation of any skin reactions).\n\nExclusion criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous randomisation in this study.\n* Previous rescreening for this study.\n* Pregnant or breastfeeding female participants.\n* Current participation (i.e., signed informed consent) in any other interventional clinical study. Treatment with an investigational medical product within 3 months or 5 half-lives (if known), whichever is longer prior to screening.\n* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol, including insufficient abdominal area for injection.\n* Intake of any medication that could influence pain perception or injection site reaction appearance (e.g., anti-coagulants, including low dose of aspirin, systemic antihistamines, pain-relieving, or anti-inflammatory medicinal products) within the last week before the intervention.\n* Intake of alcohol within the last 24 hours (self-reported) or a positive result of alcohol breath test prior to randomisation and intervention.\n* Intake of illicit drugs within the last 48 hours (self-reported) or a positive result of urine drug screening prior to screening.\n* Use of any nicotine products within the past month before screening.\n* Known active or inactive skin condition or disease, tattoos, or other interventions in the injection area that may affect pain perception or assessment of injection-site reactions.\n* Strenuous exercise within 3 days prior to the intervention.","64 Years",{"count":118,"type":22},100,[54],"The purpose of the study is to investigate the tolerability of different injection\u002Finfusion volumes and speed compared to standard practise. The order in which the different volumes and injection speeds will be given to participants will be allocated by chance. Participants will be in this clinical study for about 1 week.",[122],"Healthy Participants","NOT_YET_RECRUITING","2026-08-14",{"date":30,"type":33},{"date":59,"type":22},{"date":128,"type":22},"2026-12-11",{"name":39,"class":40},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":66},"100647600","phase-1-a-research-study-on-how-ubt251-affects-levels-of-midazolam-caffeine-and-warfarin-in-the-blood-of-participants-with-excess-body-weight-100647600","NCT07710768","A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight","An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18-65 years (both inclusive) at the time of signing the informed consent.\n* BMI between 27.0-39.9 kg\u002Fm\\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.\n* Body weight \\>=60.0 kg.\n* Considered to be generally healthy, except for overweight or obesity, based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), or glucagon (GCG) receptor agonism within 90 days before screening.\n* Use of prescription medicinal products or non-prescription drugs, including any herbal medicine known to interfere with the metabolic CYP pathways, such as perikon (St. John's Wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days (or within 5 half-lives of the medicinal product, whichever is longest) of screening, with the exception of use of routine vitamins (vitamins used within a normal dose reference interval), occasional use of acetaminophen, ibuprofen, or topical medication not reaching systemic circulation.\n* Any contraindications for the use of caffeine, midazolam, and warfarin used in the study according to Vivarin®, Midazolam®, and warfarin sodium product information.\n* Presence of clinically significant gastrointestinal disorders or symptoms of gastrointestinal disorders potentially affecting absorption of drugs or nutrients, or as judged by the investigator.\n* History of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.",{"count":138,"type":22},44,[54],"The purpose of this clinical study is to find out if UBT251 is safe and effective to be taken together with medicines, like midazolam, caffeine and warfarin in participants living with overweight or obesity.",[57,142],"Overweight",{"date":30,"type":33},{"date":145,"type":33},"2026-07-15",{"date":147,"type":22},"2027-04-07",{"name":39,"class":40},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":163,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100632101","phase-3-amaze-6-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-knee-osteoarthritis-lose-weight-and-reduce-pain-100632101","NCT07509307","AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)","AMAZE 6","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing the informed consent\n* Clinical diagnosis of knee osteoarthritis (OA) (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence \\[KL\\] grades 2 to 4 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg\n* Symptomatic knee OA with first appearance of pain in the target knee \\> 90 days prior to screening and pain in the target knee for \\> 15 days over the prior 30 days\n* Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 grams (g)\u002Fday is allowed as rescue medication up until 24 hours before those visits)\n\nKey Exclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening\n* Any joint prosthesis or joint replacement in target knee\n* Arthroscopy or injections into target knee within the last 90 days prior to screening\n* Any other joint disease in target knee including gout and pseudogout",{"count":158,"type":22},400,[25],"This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[57,142,162],"Osteoarthritis, Knee",{"date":59,"type":33},{"date":165,"type":33},"2026-04-20",{"date":167,"type":22},"2028-08-14",{"name":39,"class":40},81,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":190},"100652297","phase-3-research-study-on-how-well-oral-semaglutide-works-for-weight-loss-in-adults-with-excess-body-weight-100652297","NCT07770841","Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight","Efficacy and Safety of Once Daily Oral Semaglutide in Adults With Overweight or Obesity","OASIS 5","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Female or male (sex at birth).\n* Age 18 years or above at the time of signing the informed consent.\n* Body mass index (BMI) of\n\n  1. ≥ 27.0 kilogram per square meter (kg\u002Fm\\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease.\n\n     OR\n  2. ≥ 30.0 kg\u002Fm\\^2.\n* History of at least one self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria:\n\n* A self-reported change in body weight greater than (\\>) 5% within 90 days before screening irrespective of medical records.\n* HbA1c ≥ 6.5% (48 millimoles per mole \\[mmol\u002Fmol\\]) as measured by the central laboratory at screening.\n* Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1\u002Fgastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.",{"count":179,"type":22},450,[25],"The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.",[142,57],"2026-08-13",{"date":30,"type":33},{"date":186,"type":33},"2026-08-12",{"date":188,"type":22},"2028-04-11",{"name":39,"class":40},62,{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":198,"minAge":19,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":212},"100605046","phase-4-a-research-study-to-see-how-safe-is-eptacog-alfa-when-used-to-stop-heavy-bleeding-in-women-after-giving-birth-in-india-100605046","NCT07157423","A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India","Safety of Eptacog Alfa in Severe Postpartum Haemorrhage in India: A Phase IV Interventional Study","Inclusion Criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study except for blood loss estimation post-partum\n* Adult women aged greater than or equal to (≥) 18 years at the time of signing the informed consent and who deliver after 27 weeks diagnosed with severe postpartum haemorrhage (PPH) who fail to respond to uterotonics\n\nExclusion Criteria:\n\n* Previous participation in this study. Participation is defined as having given informed consent in this study\n* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation\n* Patient with a history of thromboembolism\n* Patient with a history of bleeding disorders\n* Patient with a history of or ongoing disseminated intravascular coagulation (DIC); haemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome, thrombotic thrombocytopenic purpura (TTP), pre-eclampsia or other severe complication of childbirth apart from severe PPH\n* Have undergone invasive obstetric procedures for the ongoing haemorrhage prior to trial enrolment (uterine balloon tamponade and external aortic compression not included)\n* Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise patient's safety or compliance with the protocol\n* Participation (i.e., signed informed consent) in any other interventional clinical study prior to screening in the current study","FEMALE",{"count":200,"type":22},64,[202],"PHASE4","This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth. If participants have heavy bleeding after giving birth then they will get the medicine eptacog alfa. This study will be conducted to get more knowledge on the safety of the medicine eptacog alfa use in these women. At first participants will receive one dose of medicine eptacog alfa. If the given dose is not helpful to stop the bleeding, participants will get one additional dose. The study will last for about 30-35 days.",[205],"Severe Postpartum Haemorrhage",{"date":183,"type":33},{"date":208,"type":33},"2025-08-26",{"date":210,"type":22},"2027-08-26",{"name":39,"class":40},14,{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":221,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},"100563138","phase-3-a-study-to-evaluate-how-well-etavopivat-works-in-people-with-sickle-cell-disease-100563138","NCT06612268","A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease","A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease","Hibiscus 2","Inclusion Criteria:\n\n* Male or female.\n* Age 12 years or above at the time of signing the informed consent.\n* Confirmed diagnosis of sickle cell disease: Documentation of sickle cell disease (SCD) genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing or screening test results from central laboratory. Molecular genotyping is not required. SCD genotype may be determined from the results of haemoglobin (Hb) electrophoresis, high-performance liquid chromatography (HPLC) or similar testing. Note that Hb electrophoresis is performed by the central laboratory at screening.\n* Have 1-15 episodes of documented vaso occlusive crises (VOC) within the 12 months prior to screening. Documentation must exist in the participant's medical record prior to randomisation. Events based solely on participant recall without supporting documentation should not be counted towards eligibility.\n* Hb greater than or equal to (≥) 5.0 and less than or equal to (≤) 10.0 g\u002FdL (greater than or equal to (≥) 50 and less than or equal to (≤) 100 g\u002FL) at screening.\n\nExclusion Criteria:\n\n* More than 15 VOCs within the past 12 months prior to screening documented in the participant's medical record. Events based solely on participant recall without supporting documentation should not be counted towards eligibility.\n* Use of voxelotor or similar agent within 28 days prior to starting study treatment or anticipated need for this agent during the study.\n* Use of a selectin antagonist (e.g., crizanlizumab, monoclonal antibody or small molecule) within 28 days or 5 half-lives (whichever is longer) prior to starting study treatment or anticipated need for such agents during the study.\n* Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or greater than or equal to 6 transfusion events in the previous 12 months (i.e., an average of 1 transfusion event every 60 days).\n* Participants who have received an RBC transfusion for any reason within 60 days of the screening period or 60 days of the randomisation day are only eligible if HbA (adult haemoglobin) less than 10% by Hb electrophoresis is documented prior to starting study treatment.\n* Receiving or use of concomitant medications that are strong inducers of CYP3A4 (cytochrome p450 3a4) within 2 weeks of starting study treatment or anticipated need for such agents during the study.\n* Use of erythropoietin or other haematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study.\n* Receipt of prior cellular-based therapy (e.g., haematopoietic cell transplant, gene modification therapy).\n* Hepatic dysfunction characterized by:\n\n  * Alanine aminotransferase (ALT) greater than 4.0 × upper limit of normal (ULN) or\n  * Direct bilirubin greater than 3.0 × ULN.\n* Participants who are not taking or are unable to take antimalarial prophylaxis at the time of consent and during the study if they live in areas of endemic malaria where prophylaxis is recommended.\n* Severe renal dysfunction (estimated glomerular filtration rate \\[eGFR\\] at screening, calculated by the central laboratory greater than 30 mL\u002Fmin\u002F1.73 m\\^ 2) or on chronic dialysis.\n* Travelled distance on standardized 6MWT below 100m at screening.","12 Years",{"count":223,"type":22},408,[25],"This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.",[227],"Sickle Cell Disease",{"date":183,"type":33},{"date":230,"type":33},"2025-02-17",{"date":232,"type":22},"2029-08-12",{"name":39,"class":40},175,{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":243,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},"100562904","phase-3-a-research-study-looking-at-long-term-treatment-with-etavopivat-in-people-with-sickle-cell-disease-or-thalassaemia-100562904","NCT06609226","A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia","An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat Study","FLORAL","Inclusion Criteria:\n\n* Participant must have ongoing participation in an etavopivat parent study for treatment of sickle cell disease (SCD) or thalassaemia and have completed at least a treatment period of the parent study.\n* Participant must have derived clinical benefit from treatment with etavopivat, as determined by the investigator.\n* Any participant with dose reduction or temporary discontinuation will need to be successfully rechallenged to the full dose of etavopivat before transferring.\n* Participants on hydroxyurea (HU), crizanlizumab or l-glutamine oral powder (Endari®) treatment at the time of consent may be eligible if they have been on a stable dose in the parent study as defined at the investigator's discretion. Necessary adjustments related to weight or age are accepted. Participants with temporary dose reductions or pauses due to medical reasons may still be considered to have a stable dose, as determined by the investigator, who will assess the impact of these adjustments based on clinical context and the participant's overall health status.\n\nExclusion Criteria:\n\n* Any disorder, except for conditions associated with SCD or thalassaemia, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Participant withdrew or had permanent treatment discontinuation from an etavopivat clinical study.\n* Participants on permanent dose reduction (greater than \\[\\>\\] 28 days or more) or ongoing temporary treatment discontinuation.\n* Use of any of the following within the timeframes prior to the transfer visit as stated:\n* Use of haemoglobin S (HbS) polymerisation inhibitors within participation of the parent study or anticipated need for this agent during this study.\n* Use of an experimental selectin antagonist (e.g., monoclonal antibody or small molecule) within the parent study or anticipated need for such agents during this study.\n* Use of erythropoietin or other haematopoietic growth factor treatment for more than 4 consecutive weeks during the parent study or anticipated need of such agents for a maintenance treatment during this study.\n* Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4 within 2 weeks of the transfer visit or anticipated need for such agents during the study.\n* Current participation in a study that is not a designated parent study, or planned participation in any other clinical study, for the duration of FLORAL.","2 Years",{"count":245,"type":22},480,[25],"Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.",[227,249],"Thalassemia",{"date":183,"type":33},{"date":252,"type":33},"2025-01-10",{"date":254,"type":22},"2030-12-30",{"name":39,"class":40},106,{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":264,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":275,"locationsCount":276},"100652029","phase-1-a-first-in-human-research-study-on-how-nnc0721-8060-works-in-people-living-with-overweight-or-obesity-100652029","NCT07767175","A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity","A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18-55 years (both inclusive) at the time of signing informed consent.\n* Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg\u002Fm\\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.\n* Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous randomisation in this study.\n* History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.\n* Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.\n* Current participation (signed informed consent) in any other interventional clinical study.\n* Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.\n* Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.\n* Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \\[mmol\u002Fmol\\]) at screening.","55 Years",{"count":266,"type":22},142,[54],"The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.",[142,57],"2026-08-11",{"date":59,"type":33},{"date":186,"type":22},{"date":274,"type":22},"2027-09-23",{"name":39,"class":40},2,{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":23,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":276},"100651146","phase-1-a-research-study-to-see-how-nnc0487-0111-affects-the-bodys-energy-use-after-a-weight-loss-in-adults-living-with-obesity-compared-to-a-low-calorie-diet-or-placebo-100651146","NCT07757087","A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo","The Effect of Once-weekly Subcutaneous NNC0487-0111 Compared to an Energy-restricted Diet or Placebo on Energy Metabolism in Adults Living With Obesity: a Randomised, Placebo-controlled Study","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18 years or older at the time of signing the informed consent.\n\nExclusion Criteria:\n\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.\n* Exposure to an investigational medicinal product before screening.\n* Any condition, or disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Anticipated change in lifestyle (e.g., eating, exercise or sleeping pattern) during the study, for example, an imminent job change to\u002Ffrom a physically demanding occupation.\n* Claustrophobia or severe discomfort of being confined in small rooms.\n* History of type 1 or type 2 diabetes mellitus.\n* Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal (GI), or endocrinological conditions.\n* Unusual meal habits (including, but not limited to, eating disorders) and special diet requirements or unwillingness to eat the food provided in the study.\n* Use of any weight lowering pharmacotherapy or pharmacotherapy that may cause weight gain, including systemic corticosteroids (except for a short course of treatment, i.e., 7-10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilisers prior to screening.\n* Use of incretin or amylin-based therapies prior to screening or previous discontinuation of long-term incretin and\u002For amylin-based therapy due to tolerability issue.\n* Physical activity of moderate to vigorous intensity for greater than (\\>) 4 hours\u002Fweek within the past 6 months before screening.",{"count":285,"type":22},120,[54],"The purpose of this clinical study is to evaluate how NNC0487-0111 affects the amount of energy the body uses in people living with obesity following weight loss. This will be compared with the amount of energy used by participants who achieve weight loss through a low-calorie diet and by participants receiving placebo (without weight loss).",[142,57],"2026-08-10",{"date":270,"type":33},{"date":292,"type":33},"2026-08-03",{"date":294,"type":22},"2028-09-18",{"name":39,"class":40},{"id":297,"slug":298,"hasResults":12,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":23,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":309,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":315},"100601580","phase-4-a-research-study-to-see-how-well-weekly-insulin-icodec-maintains-blood-sugar-levels-compared-to-daily-basal-insulins-in-adults-with-type-2-diabetes-100601580","NCT07112339","A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice","Inclusion Criteria:\n\n* Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening.\n* Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:\n\nMetformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist.\n\n* Need of intensification with basal insulin, as indicated at the discretion of the investigator.\n* Recorded HbA1c value ≥7% within the last 90 days prior to randomization.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous participation in this study. Participation is defined as signed informed consent.\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.\n* Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening.\n* Any disorder which in the investigator's opinion might jeopardize participant's safety.",{"count":304,"type":22},586,[202],"This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.",[308],"Diabetes Mellitus, Type 2",{"date":270,"type":33},{"date":311,"type":33},"2025-08-15",{"date":313,"type":22},"2028-03-23",{"name":39,"class":40},75,{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":336},"100643855","a-research-study-comparing-how-well-different-doses-of-the-medicine-ubt251-lower-blood-sugar-in-people-with-type-2-diabetes-100643855","NCT07668388","A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes","Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18-75 years (both inclusive) at the time of signing the informed consent.\n* Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening.\n* Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:\n\nmetformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.\n\n* HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol\u002Fmol)) (both inclusive) as assessed by central laboratory at screening.\n* Body mass index between 25.0 kg\u002Fm\\^2 and 50.0 kg\u002Fm\\^2 (both inclusive) at screening.\n\nExclusion Criteria:\n\n* Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.",{"count":324,"type":22},300,[326],"PHASE2","The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.",[308],"2026-08-07",{"date":289,"type":33},{"date":332,"type":33},"2026-06-22",{"date":334,"type":22},"2027-11-15",{"name":39,"class":40},70,{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":96,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":349,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":355},"100624924","a-research-study-comparing-how-well-different-doses-of-the-medicine-nnc0662-0419-lower-blood-sugar-in-people-with-type-2-diabetes-100624924","NCT07415954","A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes","Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study","Inclusion criteria\n\n* Male or female (sex at birth).\n* Age 18-75 years (both inclusive) at the time of signing the informed consent.\n* Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \\[mmol\u002Fmol\\]) (both inclusive) as assessed by central laboratory at screening.\n* Willingness to obtain a high weight loss (greater than \\[\\>\\] 25% of weight at baseline).\n\nExclusion criteria\n\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.",{"count":345,"type":22},270,[326],"This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.",[308],{"date":289,"type":33},{"date":351,"type":33},"2026-04-17",{"date":353,"type":22},"2027-10-01",{"name":39,"class":40},63,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":49,"sex":364,"minAge":19,"maxAge":116,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":373,"leadSponsor":375,"locationsCount":376},"100609898","a-research-study-looking-at-how-different-doses-of-study-medicine-inno8-work-in-the-body-of-people-with-haemophilia-a-100609898","NCT07220564","A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Peroral Doses of Inno8 in People With Haemophilia A","VOYAGER2","Inclusion Criteria:\n\n* Male\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n* Body weight greater than or equal to (≥) 45 kilograms (kgs).\n* Diagnosis of congenital haemophilia A with factor VIII (FVIII) activity less than or equal to (≤) 15 percentage (%) with or without FVIII inhibitors, based on medical records.\n\nExclusion Criteria:\n\n* Current or prior exposure to any prophylactic treatment for haemophilia A within 5 half-lives of the medicinal product by the time of screening.\n* Body mass index ≥30.0 kilogram per square meter (kg\u002Fm\\^2).\n* Increased risk of thrombosis, e.g. known history of personal or first-degree relative(s) with unprovoked deep vein thrombosis.\n* Any clinical signs or established diagnosis of venous or arterial thromboembolic disease.\n* Any known coagulation disorders other than haemophilia A.\n* Ongoing or planned immune tolerance induction therapy.\n* Presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs and\u002For nutrients, as judged by the investigator.","MALE",{"count":366,"type":22},30,[54],"This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.",[370],"Haemophilia A",{"date":289,"type":33},{"date":104,"type":33},{"date":374,"type":22},"2027-02-05",{"name":39,"class":40},33,{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":95,"maxAge":385,"enrollmentInfo":386,"targetDuration":4,"studyType":23,"phases":388,"briefSummary":389,"conditions":390,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":399},"100591356","phase-2-a-research-study-comparing-different-doses-of-cdr132l-with-placebo-on-the-structure-and-function-of-the-heart-in-people-with-heart-failure-with-preserved-ejection-fraction-and-left-ventricular-hypertrophy-100591356","NCT06979362","A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy","Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy","8212-Preserved","Inclusion Criteria:\n\n* Age 40-84 years (both inclusive) at the time of signing the informed consent\n* Documented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening\n* Clinically stable and on optimised doses and unchanged drug classes of guideline-directed HF therapy ≥45 days prior to randomisation\n* Left ventricular ejection fraction ≥50% as assessed by echocardiography at screening, measured by central laboratory\n* Left ventricular hypertrophy assessed by echocardiography at screening measured by central laboratory with any of the following:\n\n  1. LVMi (greater than) \\>88 gram per square meter (g\u002Fm\\^2) for female participants and \\>102 g\u002Fm\\^2 for male participants, using the truncated ellipsoid method measured by central laboratory\n  2. LVMi \\>95 g\u002Fm2 for female participants and \\>115 g\u002Fm2 for male participants using the linear method (cube formula).\n  3. Interventricular septum diameter measured in diastole (IVSd) in the parasternal long axis view ≥1.1 cm for female participants and ≥1.2 cm for male participants.\n* Body mass index 18.5-40 kilogram per square meter (kg\u002Fm\\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)\n* NT-proBNP ≥300 picograms per milliliter (pg\u002FmL); NT-proBNP ≥600 pg\u002FmL if atrial fibrillation\u002Fflutter is present at time of screening, measured by central laboratory\n\nExclusion Criteria:\n\n* Estimated glomerular filtration rate lesser than (\\\u003C) 30 milliliter per minute (mL\u002Fmin)\u002F1.73 square meter (m\\^2) at time of screening, measured by central laboratory\n* Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator, within 90 days prior to randomisation\n* Myocardial infarction, unstable angina pectoris or HF hospitalisation within 30 days prior to screening\n* Participants receiving intravenous HF medications within 45 days prior to randomisation\n* Participants with CRT, pacemaker or implantable cardioverter-defibrillator\n* Planned coronary revascularisation, pacemaker\u002Fcardioverter-defibrillator\u002FCRT implantation, ablation of cardiac arrythmias and valve repair\u002Freplacement at the time of randomisation\n* Stroke or transient ischemic attack within 12 months prior to randomisation\n* Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator\n* Known history of severe liver disease and\u002For alanine aminotransferase or aspartate aminotransferase \\>2.5 x upper limit of normal at screening, measured by central laboratory\n* Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy \\[HCM\\]).\n* Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis.","84 Years",{"count":387,"type":22},200,[326],"This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.",[80],"2026-08-04",{"date":393,"type":33},"2026-08-05",{"date":395,"type":33},"2025-06-27",{"date":397,"type":22},"2028-07-25",{"name":39,"class":40},117,{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":23,"phases":409,"briefSummary":410,"conditions":411,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":419},"100636855","phase-3-amaze-4-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-obstructive-sleep-apnoea-treated-with-positive-airway-pressure-lose-weight-and-improve-sleep-apnoea-100636855","NCT07571109","AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Obstructive Sleep Apnoea Treated With Positive Airway Pressure (AMAZE 4)","AMAZE 4","Key Inclusion Criteria:\n\n* Male or female (sex at birth)\n* Age 18 years or above at the time of signing informed consent\n* Previously diagnosed moderate-to-severe OSA with an AHI ≥ 15, as diagnosed with polysomnography (PSG), home sleep apnoea test (HSAT), or other method that meets local guidelines prior to screening\n\nKey Exclusion Criteria:\n\n* Glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol\u002Fmol) as measured by the central laboratory at screening\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records\n* Any planned or previous surgery within 90 days prior to screening for sleep apnoea, including septoplasty, turbinoplasty, or other ear, nose, and throat surgeries, including tonsillectomy and adenoidectomy\n* Significant craniofacial abnormalities that may affect breathing at baseline, for example Treacher Collins syndrome and Pierre Robin Sequence\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonist (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening",{"count":324,"type":22},[25],"This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.",[57,142,412],"Obstructive Sleep Apnoea",{"date":391,"type":33},{"date":415,"type":33},"2026-05-05",{"date":417,"type":22},"2028-08-21",{"name":39,"class":40},92,{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":264,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":276},"100636492","phase-1-a-research-study-investigating-how-a-new-medicine-nnc0113-5840-works-in-people-with-overweight-or-obesity-100636492","NCT07566390","A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity","A First in Human Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC0113-5840 in Participants With Overweight or Obesity","Inclusion Criteria:\n\n1. Male or female\n2. Age 18-55 years (both inclusive) at the time of signing the informed consent.\n3. Body mass index (BMI) between 25.0 and 34.9 kilogram per meter square (kg\u002Fm2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.\n4. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit and visit 2, day -1, as judged by the investigator.\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to study intervention(s) or related products.\n2. Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n3. Glycosylated haemoglobin (HbA1c) more than or equal to (≥) 6.5 percent (%) \\[48 millimole per mole (mmol\u002Fmol)\\] at screening.",{"count":428,"type":22},48,[54],"The purpose of this clinical study is to find out if NNC0113-5840 is safe for treating people with excess body weight. There are 2 study treatments in this study, participants will get either NNC0113-5840 (the product being tested) or Placebo (treatment that has no active medicine in it), Which treatment participants get is decided by chance.",[57,142],{"date":391,"type":33},{"date":434,"type":33},"2026-05-01",{"date":436,"type":22},"2026-12-26",{"name":39,"class":40},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":23,"phases":448,"briefSummary":449,"conditions":450,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":452,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":458},"100633937","phase-3-amaze-2-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-type-2-diabetes-lose-weight-100633937","NCT07533175","AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)","AMAZE 2","Inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18 years or above at the time of signing informed consent.\n* Diagnosed with type 2 diabetes mellitus more than equal to (≥) 180 days before screening.\n* Treatment with lifestyle intervention, and\u002For 0-3 marketed oral antidiabetic drugs (OAD)s (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i), thiazolidinediones, or sulfonylureas (SU) as a single agent or in combination) according to local label. Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) before screening.\n* Haemoglobin A1c (HbA1c) 7-10% \\[53-86 (millimoles per mole) mmol\u002Fmol\\] (both inclusive) as measured by the central laboratory at screening.\n\nExclusion Criteria:\n\n* Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than (\\\u003C) 30 milliliter per minute per meter square (mL\u002Fmin\u002F1.73 m\\^2) \\[2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\\], at screening.\n* Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) before screening or are expected to require treatment after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8.\n* Recurrent severe hypoglycaemic episodes within the last year as judged by the investigator.\n* Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.",{"count":447,"type":22},630,[25],"The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[451,142,57],"Diabetes Mellitus",{"date":391,"type":33},{"date":454,"type":33},"2026-04-13",{"date":456,"type":22},"2028-08-07",{"name":39,"class":40},74,{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":98},"100650155","phase-3-a-research-study-to-compare-two-different-versions-of-injectable-cagrilintide-and-placebo-in-people-with-excess-body-weight-100650155","NCT07745504","A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight","A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity","RENEW 4","Inclusion criteria:\n\n* Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18 years or above at the time of signing the informed consent.\n* Body mass index (BMI) greater than or equal to (\\>=) 30.0 kilograms per square meter (kg\u002Fm\\^2), or BMI \\>= 27.0 kg\u002Fm\\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.\n\nExclusion criteria:\n\n* History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).\n* Previous dosing of marketed or non-marketed amylin-based compounds.\n* Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.",{"count":468,"type":22},285,[25],"The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.",[142,57],"2026-07-30",{"date":391,"type":33},{"date":391,"type":22},{"date":476,"type":22},"2027-07-06",{"name":39,"class":40},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":498},"100636340","phase-3-a-research-study-to-look-at-how-two-different-doses-of-cagrisema-and-one-dose-of-semaglutide-help-people-living-with-obesity-with-or-without-type-2-diabetes-lose-weight-100636340","NCT07564414","A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight","A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes","Inclusion Criteria :\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18 years or above at the time of signing the informed consent.\n* BMI≥ 35.0 kg\u002Fm\\^2.\n* Participants without T2D: No history of T2D and HbA1c \\\u003C 6.5% (48 millimoles per mole (mmol\u002Fmol)) Participants with T2D: A history of T2D and HbA1c \\\u003C 10% (\\\u003C 86 mmol\u002Fmol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol\u002Fmol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised.\n\nExclusion Criteria:\n\n* A self-reported change in body weight \\> 5% within 90 days before screening, irrespective of medical records.\n* Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.",{"count":486,"type":22},2500,[25],"This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks",[57,490],"Type 2 Diabetes","2026-07-29",{"date":472,"type":33},{"date":494,"type":33},"2026-05-21",{"date":496,"type":22},"2028-04-19",{"name":39,"class":40},303,{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":49,"sex":18,"minAge":19,"maxAge":264,"enrollmentInfo":506,"targetDuration":4,"studyType":23,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":66},"100626549","phase-1-a-study-to-see-how-safe-a-new-medicine-nnc6989-0001-is-in-healthy-people-living-with-overweight-or-obesity-100626549","NCT07437079","A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity","A First Human Dose Study Investigating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Single and Multiple Ascending Doses of NNC6989-0001 in Healthy Participants With Overweight or Obesity","Inclusion Criteria:\n\n* Male or female of non-childbearing potential.\n* Age 18-55 years (both inclusive) at the time of signing the informed consent.\n* Body mass index (BMI) (at screening) ≥ 25.0 and ≤ 34.9 kg\u002Fm\\^2 for Part A (SAD part) and BMI (at screening) ≥ 25.0 and ≤ 39.9 kg\u002Fm\\^2 for Part B (MAD part) and Part C (meal timing and potentially meal composition).\n* Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram, and clinical laboratory tests performed during the screening visit, as judged by the investigator.\n\nExclusion Criteria:\n\n* Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Any clinically significant body weight change (≥5 % self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening.\n* Treatment with any GLP-1 RA or a medication with GLP-1 activity within 90 days before screening\n* Use of prescription or non-prescription medicinal products within 14 days before screening. This includes over the counter medicines such as laxatives, mineral oil, and fat-blocking supplements. Routine multivitamin\u002Fmineral supplements at labelled daily doses are permitted; other non-prescription supplements (e.g., high-dose vitamins, weight-loss supplements) are not permitted. Occasional use of over-the-counter acetaminophen or NSAIDs at their labelled doses for mild pain is permitted.",{"count":507,"type":22},132,[54],"This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity. NNC6989-0001 is still being tested in studies and is not yet available for prescription by doctors. In this study, participants will receive either NNC6989-0001 or a placebo; which treatment each participant receives will be decided by chance.",[142,57],"2026-07-28",{"date":491,"type":33},{"date":514,"type":33},"2026-02-24",{"date":516,"type":22},"2027-01-21",{"name":39,"class":40},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":95,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":528,"phases":4,"briefSummary":529,"conditions":530,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":538},"100633913","a-real-world-study-to-investigate-cardiovascular-risk-profile-among-newly-diagnosed-type-2-diabetes-mellitus-t2dm-participants-100633913","NCT07532863","A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants","A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia","CRISTALSEA","Inclusion Criteria:\n\n* Aged greater than equal to (≥) 40 and less than (\\\u003C) 70 years\n* Male or female\n* Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023\n\nExclusion Criteria:\n\n* If any exclusion criterion is met, the participant will be excluded from the study.\n* T1DM or gestational diabetes\n* Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM\n* Pregnant women\n* With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease\n* Died within 12 months after first diagnosis of T2DM\n* Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM","70 Years",{"count":158,"type":22},"OBSERVATIONAL","The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.",[308],"2026-07-27",{"date":511,"type":33},{"date":534,"type":33},"2026-03-13",{"date":536,"type":22},"2027-03-27",{"name":39,"class":40},6,""]